J.ophthalmol.(Ukraine).2015;6:42-45.

https://doi.org/10.31288/oftalmolzh201564245

Quercetin and lipoate effect on the glutathione system in retina in terms of diabetes simulation

O.A. Moroz, PhD in Medical Sciences

А. Novak Transcarpathian Regional Clinical Hospital

Ophthalmology Department 

(Uzhgorod, Ukraine)

E-mail: moroz.oleg@gmail.com

Keywords: streptozotocin-induced diabetes, retina, glutathione, quercetin, lipoic acid, experimentIntroduction. The relevance of the work lies in the research of the quercetin and lipoate effect in terms of experimental diabetes treatment.

Objective. To study the quercetin and lipoate effect on the glutathione system in retina in terms of diabetes progress process (in two and six months).

Materials and methods. The research was conducted using albino rats. Experimental animals were divided into four groups: the first one – control group (14 rats); the second one – experimental group (14 rats), untreated animals with developing diabetes; the third one – experimental group (12 rats), animals with developing diabetes and lipoic acid administration; the fourth one – experimental group (15 rats), animals with developing diabetes and quercetin administration. Reduced and oxidized glutathione content was determined in retinal homogenates.

Results. Lipoic acid and quercetin use enhanced the reduced glutathione level by 107.2 and 84.3% in 2 months in terms of research, and by 134.8% and 113.0 in 6 months after the diabetes progress compared to the group of untreated animals.

Conclusion. In terms of streptozotocin-induced diabetes progress the decrease of coenzyme (reduced) glutathione form by 61.9% (in 2 months) and by 68.3% (in 6 months) was determined. Lipoic acid and quercetin medical products administration had a normalizing effect on the retinal metabolism, which is manifested in the reduced glutathione levels increase by 107.2 and 84.3% (in 2 months) and by 134.8 and 113.0% (in 6 months). The lipoic acid application creates a more distinct normalizing effect on the glutathione level.

 

References

  1. Gogina IF, Andriu LV, Ogranovich OE. [Diabetic angio-, retino-, neuropathy: patogenesis, clinic, treatment], Lviv: Liga press. 2000:186. Ukrainian.
  2. Kravchuk EA. [The role of free radical oxidation in pathogenesis of eye diseases]. Vestnik oftalmologii. 2004;5:48-51. Russian.
  3. Kryzhanovskaya TV. [Nosotropic rehabilitation aspects of diabetic retinopathy patients]. Mater. of 2nd Inter. Conf. ‘Modern Aspects of Cardioendocrinopathy of Ocular Organ’. K. 2005:73-74. Russian.
  4. Leus NF. [Metabolic development mechanisms and pharmacotherapy aspects of diabetic retinopathy]. Oftalmol Zh. 2003;5:75-80. Russian.
  5. Maltsev EV, Rodin SS, Chernyaeva SN. [Diabetic retinopathy, mechanisms of development]. Oftalmol Zh. 2003;2:82-88. Russian.
  6. Nasledov A. [SPSS computer data analysis in psychology and social sciences]. Spb. Peter. 2005:416. Russian.
  7. Nedzvetskaya OV. [Modern trends in diabetic retinopathy treatment]. Intern. Med. J. 2000; 3:56-58. Russian.
  8. [New methods of biochemical analysis]. Leningrad university edition. 1991:395. Russian.
  9. Olejnik ТV. [Possibility of correcting the glutathione levels within the retina during the streptozotocin-induced diabetes progress]. Oftalmol Zh. 2007;3:68-72. Russian.
  10. Pavlyuchenko KP, Mogilevsky SYu, Chujko AL. [The state of antioxidant enzymes system in the retina during experimental diabetes and application of vitamin В6]. Oftalmol Zh. 2011;3:73-78. Russian.
  11. Pavlyuchenko KP, Olejnik ТV. [Investigation of glutathione in the retina in rats with streptozotocin-induced diabetes]. Issues of ecological and medical genetics and clinical immunology. Collection of scientific works. 2004;8(61):355-362. Russian.
    Crossref
  12. Sidorova MV. [Diabetic retinopathy. Pathogenesis, clinic, treatment]. K. SMP “AVERS”. 2006:156. Russian.
  13. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am. J. Ophthalmol. 2001;32:760-776.
    Crossref
  14. Bayness JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
    Crossref
  15. Bergmeyer HU. Methoden der enzymatischen Analyse. Herausgegeben von H. U. Bergmeyer. Berlin. 1986:2220.
  16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
  17. Dervan E, Lillis D, Flynn L. Factors that influence the patient uptake of diabetic retinopathy screening. Irish. J. Med. Sci. 2008;177:303-308.
  18. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem. Pharmacol. 2002;64:1019-1026.
  19. Fong DS, Aiello LP, Ferris FL, Klein RK. Diabetic retinopathy. Ophthalmol. 2004;27:2540-2553.
  20. Lang GE. Pharmacological treatment of diabetic retinopathy. Ophthalmologica. 2007;221:112-117.
    Crossref
  21. Riley M, Meyer R, Yates E. Glutathione in the aqueous humor of human and other species. Invest. Ophthalmol. Vis. Sci. 1980;19:94-96.
  22. Speicher MA, Danis RP, Criswell M. Pharmacologic therapy for diabetic retinopathy. Expert Opion Emerg Drugs. 2003;8(1):239-250.
    Crossref